分子標的薬，メシル酸イマチニブ（グリベック®）の薬理学的特性および臨床効果

摘要: Imatinib mesilate (Glivec) is a protein-tyrosine kinase inhibitor that potently inhibits the Bcr-Abl tyrosine as well receptors for platelet-derived growth factor (PDGF) and stem cell (SCF), c-Kit, at in vitro cellular assay levels. Since plays key role chronic myelogenous leukemia (CML) patients, treatment with imatinib could be promising therapeutic approach to CML. was shown inhibit proliferation of bcr-abl-positive lines suppress formation colonies cells derived from bone marrow CML patients. This compound induced apoptosis variety cells. Moreover, vivo data indicated tumors mice. As profile expected preclinical studies, showed impressive hematological cytogenic responses clinical trials, including interferon-alpha-resistant or intolerant